Sotrovimab (VIR 7831) is a human IgG1?? monoclonal antibody designed to target and neutralize a broad range of sarbecoviruses, including SARS-CoV-2 and SARS-CoV-1. This antibody is derived from S309, a precursor known for its potent neutralizing capabilities. Sotrovimab features an extended half-life and enhanced bioavailability, particularly within the respiratory mucosa. Its mechanism of action facilitates the clearance of virus-infected cells and is effective in preventing the progression of COVID-19 when administered early in the disease course. This makes Sotrovimab a valuable tool in therapeutic interventions against COVID-19 and related coronavirus infections.
Sotrovimab (VIR 7831) is a human IgG1?? monoclonal antibody designed to target and neutralize a broad range of sarbecoviruses, including SARS-CoV-2 and SARS-CoV-1. This antibody is derived from S309, a precursor known for its potent neutralizing capabilities. Sotrovimab features an extended half-life and enhanced bioavailability, particularly within the respiratory mucosa. Its mechanism of action facilitates the clearance of virus-infected cells and is effective in preventing the progression of COVID-19 when administered early in the disease course. This makes Sotrovimab a valuable tool in therapeutic interventions against COVID-19 and related coronavirus infections.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
